参考文献/References:
[1] Nakamura M,Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy[J]. Nat Rev Cardiol,2018,15(7):387-407.
[2] Lin HB,Naito K,Oh Y,et al. Innate immune Nod1/RIP2 signaling is essential for cardiac hypertrophy but requires mitochondrial antiviral signaling protein for signal transductions and energy balance[J]. Circulation,2020,142(23):2240-2258.
[3] Tupik JD,Nagai-Singer MA,Allen IC. To protect or adversely affect? The dichotomous role of the NLRP1 inflammasome in human disease[J]. Mol Aspects Med,2020,76:100858.
[4] He Y,Hara H,Nú?ez G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem Sci,2016,41(12):1012-1021.
[5] Fritz JH,Ferrero RL,Philpott DJ,et al. Nod-like proteins in immunity,inflammation and disease[J]. Nat Immunol,2006,7(12):1250-1257.
[6] Franchi L,Mu?oz-Planillo R,Nú?ez G. Sensing and reacting to microbes through the inflammasomes[J]. Nat Immunol,2012,13(4):325-332.
[7] Travassos LH,Carneiro LA,Ramjeet M,et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry[J]. Nat Immunol,2010,11(1):55-62.
[8] Suzuki T,Franchi L,Toma C,et al. Differential regulation of caspase-1 activation,pyroptosis,and autophagy via Ipaf and ASC in Shigella-infected macrophages[J]. PLoS Pathog,2007,3(8):e111.
[9] da Silva Correia J,Miranda Y,Austin-Brown N,et al. Nod1-dependent control of tumor growth[J]. Proc Natl Acad Sci U S A,2006,103(6):1840-1845.
[10] Richardson WM,Sodhi CP,Russo A,et al. Nucleotide-binding oligomerization domain-2 inhibits toll-like receptor-4 signaling in the intestinal epithelium[J]. Gastroenterology,2010,139(3):904-917.e6.
[11] Zamboni DS,Kobayashi KS,Kohlsdorf T,et al. The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection[J]. Nat Immunol,2006,7(3):318-325.
[12] Wright EK,Goodart SA,Growney JD,et al. Naip5 affects host susceptibility to the intracellular pathogen Legionella pneumophila [J]. Curr Biol,2003,13(1):27-36.
[13] Koonin EV,Aravind L. The NACHT family—A new group of predicted NTPases implicated in apoptosis and MHC transcription activation[J]. Trends Biochem Sci,2000,25(5):223-224.
[14] Bouskra D,Brezillon C,Berard M,et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis[J]. Nature,2008,456(7221):507-510.
[15] Halle A,Hornung V,Petzold GC,et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta[J]. Nat Immunol,2008,9(8):857-865.
[16] Mezzaroma E,Toldo S,Farkas D,et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse[J]. Proc Natl Acad Sci U S A,2011,108(49):19725-19730.
[17] Kawaguchi M,Takahashi M,Hata T,et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury[J]. Circulation,2011,123(6):594-604.
[18] Sandanger O,Ranheim T,Vinge LE,et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury[J]. Cardiovasc Res,2013,99(1):164-174.
[19] Guo H,Callaway JB,Ting JP. Inflammasomes:mechanism of action,role in disease,and therapeutics[J]. Nat Med,2015,21(7):677-687.
[20] Mangan MSJ,Olhava EJ,Roush WR,et al. Targeting the NLRP3 inflammasome in inflammatory diseases[J]. Nat Rev Drug Discov,2018,17(9):688.
[21] Franchi L,Eigenbrod T,Munoz-Planillo R,et al. The inflammasome:a caspase-1-activation platform that regulates immune responses and disease pathogenesis[J]. Nat Immunol,2009,10(3):241-247.
[22] Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family[J]. Annu Rev Immunol,2009,27:519-550.
[23] Fink SL,Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages[J]. Cell Microbiol,2006,8(11):1812-1825.
[24] Xiao H,Li H,Wang JJ,et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon beta-adrenergic insult[J]. Eur Heart J,2018,39(1):60-69.
[25] Dang S,Zhang ZY,Li KL,et al. Blockade of β-adrenergic signaling suppresses inflammasome and alleviates cardiac fibrosis[J]. Ann Transl Med,2020,8(4):127.
[26] Suetomi T,Willeford A,Brand CS,et al. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+/calmodulin-dependent protein kinase Ⅱ δ Signaling in cardiomyocytes are essential for adverse cardiac remodeling[J]. Circulation,2018,138(22):2530-2544.
[27] Willeford A,Suetomi T,Nickle A,et al. CaMKⅡδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis[J]. JCI Insight,2018,3(12):e97054.
[28] Wang Y,Liu X,Shi H,et al. NLRP3 inflammasome,an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases[J]. Clin Transl Med,2020,10(1):91-106.
[29] Anker SD,von Haehling S. Inflammatory mediators in chronic heart failure:an overview[J]. Heart,2004,90(4):464-470.
[30] Dick SA,Epelman S. Chronic heart failure and inflammation:what do we really know?[J]. Circ Res,2016,119(1):159-176.
[31] Chen Y,Zeng M,Zhang Y,et al. Nlrp3 deficiency alleviates angiotensin Ⅱ-induced cardiomyopathy by inhibiting mitochondrial dysfunction[J]. Oxid Med Cell Longev,2021,2021:6679100.
[32] Hornung V,Bauernfeind F,Halle A,et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization[J]. Nat Immunol,2008,9(8):847-856.
[33] Gaidt MM,Ebert TS,Chauhan D,et al. The DNA inflammasome in human myeloid cells is initiated by a STING-cell death program upstream of NLRP3[J]. Cell,2017,171(5):1110-1124.e18.
[34] Li N,Zhou H,Wu H,et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction,inflammation,apoptosis and pyroptosis by activating NLRP3[J]. Redox Biol,2019,24:101215.
[35] Lim S,Lee ME,Jeong J,et al. sRAGE attenuates angiotensin Ⅱ-induced cardiomyocyte hypertrophy by inhibiting RAGE-NFkappaB-NLRP3 activation[J]. Inflamm Res,2018,67(8):691-701.
[36] Li X,Zhu Q,Wang Q,et al. Protection of sacubitril/valsartan against pathological cardiac remodeling by inhibiting the NLRP3 inflammasome after relief of pressure overload in mice[J]. Cardiovasc Drugs Ther,2020,34(5):629-640.
[37] Xu L,Balzarolo M,Robinson EL,et al. NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction[J]. Cardiovasc Res,2021:cvab349.
[38] Byrne NJ,Soni S,Takahara S,et al. Chronically elevating circulating ketones can reduce cardiac inflammation and blunt the development of heart failure[J]. Circ Heart Fail,2020,13(6):e006573.
[39] Ding YY,Li JM,Guo FJ,et al. Triptolide upregulates myocardial forkhead helix transcription factor p3 expression and attenuates cardiac hypertrophy[J]. Front Pharmacol,2016,7:471.
[40] Pan XC,Liu Y,Cen YY,et al. Dual role of triptolide in interrupting the NLRP3 inflammasome pathway to attenuate cardiac fibrosis[J]. Int J Mol Sci,2019,20(2):360.
[41] Coll RC,Robertson AA,Chae JJ,et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases[J]. Nat Med,2015,21(3) :248-255.
[42] Gan W,Ren J,Li T,et al. The SGK1 inhibitor EMD638683,prevents angiotensinⅡ-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation[J]. Biochim Biophys Acta Mol Basis Dis,2018,1864(1):1-10.
[43] Sano S,Oshima K,Wang Y,et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome[J]. J Am Coll Cardiol,2018,71(8):875-886.
[44] Zhao M,Zhang J,Xu Y,et al. Selective inhibition of NLRP3 inflammasome reverses pressure overload-induced pathological cardiac remodeling by attenuating hypertrophy,fibrosis,and inflammation[J]. Int Immunopharmacol,2021,99:108046.
[45] Tang X,Pan L,Zhao S,et al. SNO-MLP (S-nitrosylation of muscle LIM protein) facilitates myocardial hypertrophy through TLR3 (Toll-like receptor 3)-mediated RIP3 (receptor-interacting protein kinase 3) and NLRP3 (NOD-like receptor pyrin domain containing 3) inflammasome activation[J]. Circulation,2020,141(12):984-1000.
[46] Wang F,Liang Q,Ma Y,et al. Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS/NLRP3/Caspase-1 pathway[J]. Free Radic Biol Med,2022,182:171-181.
[47] Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[48] Everett BM,Cornel JH,Lainscak M,et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure[J]. Circulation,2019,139(10):1289-1299.